Mylan has announced that it will acquire Meda, which markets a number of OINDPs, including Dymista, Astelin, and Astepro nasal sprays; the Aerospan MDI; and the Novopulmon Novolizer and Formatris Novolizer DPIs. Meda had previously rejected acquisition by Mylan, but the Meda board now recommends that shareholders accept the offer, which is valued at SEK 60.3 billion ($7.2 billion).
According to Mylan, “Mylan and Meda have a highly complementary therapeutic presence, which will create a leading global player in respiratory/allergy, and achieve critical mass in dermatology and pain, offering greater opportunities for growth in these categories.” Executives from both Mylan and Meda reiterated the importance of the combined respiratory/allergy portfolio to the combined company.
Read the Mylan press release.
